Clinical Trial Update: Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 safety trial evaluating soluble ferric pyrophosphate (SFP) added to dialysate for patients with chronic kidney disease on chronic hemodialysis; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Soluble Ferric Pyrophosphate (SFP) in dialysate (soluble ferric pyrophosphate)

Snippet

Sponsor: Rockwell Medical Technologies, Inc. | Conditions: End Stage Renal Disease, Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-04-21